Loading
A phase 3 trial of Epcoritamab in diffuse large b-cell lymphoma, run by Genmab, active and no longer recruiting.
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China is a phase 3 interventional study registered as NCT07226752 by Genmab, with 72 participants enrolled, started 2022-10-08 and due to reach its primary completion in 2025-10-13. Interventions recorded: Epcoritamab, Investigator's Choice Chemotherapy. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).